Abstract
Background Liver cancer is one of the cancers that consistently ranks among the top five cancers in terms of incidence and mortality in many countries. However, false-positive results on enhanced CT can lead to misdiagnosis and incorrect surgery or treatment, while false-negative results on enhanced CT can lead to missed diagnosis and delayed treatment. There is an urgent need to find convenient, cost-effective and non-invasive diagnostic methods to reduce the false-positive rate of ultrasound and the false-negative and false-positive rates of enhanced CT for liver tumors. The purpose of this study is to evaluate the diagnostic value of YiDiXie™-HS, YiDiXie™-SS and YiDiXie™-D in liver tumors.
Patients and methods This study finally included 217 subjects (the malignant group, n=185; the benign group, n=32). Remaining serum samples from the subjects were collected and tested using the YiDiXie™ all-cancer detection kit, which was applied to assess the sensitivity and specificity of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D, respectively.
Results The sensitivity of YiDiXie™-SS was 98.9% (96.1% - 99.8%) and its specificity was 68.8% (51.4% - 82.0%). This means that YiDiXie™-SS has very high sensitivity and high specificity in liver tumors.YiDiXie™-HS has a sensitivity of 88.1% (82.7% - 92.0%) and its specificity is 84.4% (68.2% - 93.1%). This means that YiDiXie™-HS has high sensitivity and high specificity in liver tumors.YiDiXie™-D has a sensitivity of 72.4% (65.6% - 78.4%) and its specificity is 93.8% (79.9% - 98.9%). This means that YiDiXie™-D has high sensitivity and very high specificity in liver tumors.YiDiXie™-SS has a sensitivity of 99.2% (95.8% - 100%) and a specificity of 66.7% (39.1% - 86.2%) in patients with positive enhanced CT. This means that the application of YiDiXie™-SS reduces the false-positive rate of enhanced CT by 66.7% (39.1% - 86.2%) with essentially no increase in the leakage of malignant tumors.YiDiXie™-HS has a sensitivity of 89.1% (95% CI: 78.2% - 94.9%) in patients with a negative enhanced CT, and its specificity is 85.0% (64.0% - 94.8%). This means that YiDiXie™-HS reduces the false-negative rate of enhanced CT by 85.0% (64.0% - 94.8%). YiDiXie™-D has a sensitivity of 73.1% (64.9% - 80.0%) and a specificity of 91.7% (64.6% - 99.6%) in patients with positive enhanced CT. This means that YiDiXie™-D reduces the false-positive rate of enhanced CT by 91.7% (64.6% - 99.6%). YiDiXie™-D has a sensitivity of 70.9% (95% CI: 57.9% - 81.2%) and a specificity of 95.0% (95% CI: 76.4% - 99.7%) in patients with negative enhanced CT. This means that YiDiXie ™ -D reduces the false-negative rate of enhanced CT by 70.9% (95% CI: 57.9% - 81.2%) while maintaining high specificity.
Conclusion YiDiXie™-SS has very high sensitivity and high specificity in liver tumors. YiDiXie™-HS has high sensitivity and high specificity in liver tumors. YiDiXie™-D has high sensitivity and very high specificity in liver tumors. YiDiXie™-SS significantly reduces the false positive rate of liver-enhanced CT with essentially no increase in delayed treatment of malignant tumors. YiDiXie™-HS significantly reduces the false-negative rate of enhanced CT. YiDiXie™-D can significantly reduce the false-positive rate of enhanced CT or significantly reduce the false-negative rate of enhanced CT while maintaining a high specificity. The YiDiXie™ test has significant diagnostic value in liver tumors, and is expected to solve the problems of “high false-positive rate” and “high false-negative rate” of enhanced CT in liver tumors.
Clinical trial number ChiCTR2200066840.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ChiCTR2200066840
Funding Statement
This work was supported by Shenzhen High-level Hospital Construction Fund, Clinical Research Project of Peking University Shenzhen Hospital (LCYJ2020002, LCYJ2020015, LCYJ2020020, LCYJ2017001).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Peking University Shenzhen Hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The results were updated. Tabel 2-8 were reviesed.
Data Availability
All data produced in the present study are contained in the manuscript.
